CD4 and neoplasm: Compared to the control and αPD-L1 groups, the SB and SB+αPD-L1 groups tended to have higher percentages of CD8+ T cells (Figure 7D), despite not having more lymphocytes, CD3+ T cells, and CD4+ T cells (Figures 7A–C), suggesting that SB plus αPD-L1 might boost the tumor immune microenvironment.